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ABSTRACT
Mechanical circulatory support is increasingly used as a long-term treatment option for patients with end-stage
heart failure. Patients with implanted ventricular assist devices are at high risk for a range of diverse medical
urgencies and emergencies. Given the increasing prevalence of mechanical circulatory support devices, this
expert clinical consensus document seeks to help inform emergency medicine and prehospital providers
regarding the approach to acute medical and surgical conditions encountered in these complex patients.
Mechanical circulatory support is a viable long-term treatment option for patients with end-
stage heart failure. As the range of indications for
implantation of ventricular assist devices grows, so
does the number of patients who live with durable
support. These patients are at high risk for medical
urgencies and emergencies (Table 1). This article is an
emergency medicine–focused summary of a consensus
document written collaboratively by the Heart Failure
Society of America (HFSA), Society for Academic
Emergency Medicine (SAEM), and International Soci-
ety for Heart and Lung Transplantation (ISHLT).1 It
aims to educate emergency medicine and prehospital
providers managing patients with left ventricular assist
devices (LVADs).
OVERVIEW OF VENTRICULAR ASSIST
DEVICES
Mechanical circulatory support is a major advance in
the treatment of patients with end-stage heart failure.2
Currently, there are three recognized indications for
the use of LVADs: 1) bridge to transplantation
(BTT), 2) destination therapy for patients ineligible
for heart transplant, and 3) bridge to myocardial
recovery.3
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Volumes and Survival
According to the eighth annual Interagency Registry
for Mechanically Assisted Circulatory Support
(INTERMACS) report, there were a total of 22,866
VAD implants from June 2006 to December 2016.
Of these, 18,987 were primary implants for left ven-
tricular support.4
Left ventricular assist devices offer superior survival
when compared to optimal medical management in
patients who are ineligible for cardiac transplantation.
For continuous-flow (CF) devices implanted since
2008, the overall 1-year survival is 81% and 2-year sur-
vival is 70%.5
LVAD “Anatomy”
Contemporary LVADs consist of an “inflow” cannula
that drains the left ventricle and an “outflow” graft to
a central artery—usually the ascending or descending
aorta. Other internal components consist of the pump
and part (20–30 cm) of the driveline, containing wires
that power and control the pump. The driveline typi-
cally exits through the upper abdominal wall. External
components are a controller and an external power
source (Figure 1). Most current LVADs provide CF
through a rotary pump, resulting in blood flow with
reduced or no pulsatility.6 However, the HeartMate 3
(Abbott) is a fully magnetically levitated pump that
provides an artificial pulse (once every 2 seconds, the
pump modifies its speed) that was approved for BTT
in 2017.7,8
CLINICAL ASPECTS SPECIFIC TO LVAD
PATIENTS
Assessing Equipment
While evaluating a patient with an LVAD, one should
determine the make and model of the pump. All
LVADs have an external driveline connected to a con-
trol device and power source. Locate the driveline,
which allows the pump to receive information and
power to run the LVAD system. This cable should be
attached at one end to the implanted pump and con-
nected to the controller.
Figure 1. Components of a typical LVAD. A CF LVAD consists of a
pump connected to the cardiac apex and ascending aorta via an
inflow cannula and outflow graft, respectively; a percutaneous drive-
line that exits the skin on the right; and a system controller that is
typically worn on a belt. Power to the controller and pump is pro-
vided by external batteries or a power-based unit. Adapted from
Mehra et al.7 with permission. CF = continuous flow; LVAD = left
ventricular assist device.
Table 1
Common Emergencies in Patients With VADs





























VAD = ventricular assist device.
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The dressing on the abdominal wall where the driv-
eline exits the skin should be dry and intact. Patients
will wear either an abdominal binder or an anchor
device to secure the driveline. Look under binders and
dressings to inspect the entirety of the line. The
anchor or binder should be kept in place during trans-
port and treatment.
The size and configuration of controllers differ by
manufacturer. The controller communicates with the
pump and displays pump parameters (e.g., speed, flow,
power) and alarms for both advisory and hazardous con-
ditions. The controller accommodates two power sources
—either dual batteries or one battery plus an AC/DC
adapter. Dual batteries can provide anywhere from 8 to
12 hours of support while patients are active. The per-
centage of charge remaining in each battery can be deter-
mined by pushing the button on the top of the battery.
All patients should have an extra controller and bat-
teries as backup equipment. Exchange the primary
controller (attached to the patient) for the backup con-
troller only when indicated by controller alarms, such
as “controller fault, change controller” and with the
guidance of a provider trained to perform this
exchange. Prehospital personnel are advised to trans-
port a patient’s backup LVAD equipment.
LVAD Parameters
Pump function and flow, displayed on the controller,
are the “vital signs” of the LVAD. A typical display
shows blood flow (liters/min), pump rotary speed (ro-
tations/min), and power consumption (Watts). LVAD
flow is calculated based on rotary speed and power
consumption and approximates cardiac output.
Device Alarms
The controller has visual and auditory alarms that
indicate problems with the pump, controller, connec-
tions, or power supply. Address alarms by first look-
ing at the controller and reading the condition.
Contacting the implant center or the manufacturer’s
clinical specialist and/or accessing online support are
critical for managing alarms.
Antithrombotic Therapy
Antithrombotic therapy is necessary for all patients
with VADs. Typically, patients are maintained on war-
farin with an international normalized ratio (INR) tar-
get of 2.0 to 3.0 and 81 to 325 mg of aspirin daily.
Some VAD programs use dipyridamole or clopidogrel
as additional antiplatelet therapy (for example, in
patients with a history of threatened pump thrombosis
or transient ischemic attack), but there are no support-
ive data. Reversal of warfarin with vitamin K, fresh-fro-
zen plasma, or prothrombin concentrate complex may
be considered when treating life-threatening bleeding
events or preparing for emergent surgery.
Patient Assessment: Vital Signs
The ability to obtain vital signs in LVAD recipients
depends on the extent that remaining native ventricular
function can generate pulsatile blood flow. For most
patients, the absence of a pulse is a normal finding and
differences in systolic and diastolic blood pressure are
undetectable by automatic and manual sphygmo-
manometers.9 A vascular Doppler can be used to assess
blood pressure—it is commonly assumed that the first
sound heard approximates the mean arterial pressure
(MAP), yet studies show this may be closer to the systolic
pressure.10 Regardless, we suggest using the Doppler
opening pressure as a surrogate for MAP, with current
ISHLT guidelines recommending a mean blood pressure
goal of ≤80 mm Hg.11 Oxygen saturation is another vital
sign that might be inaccurate, as pulse oximetry depends
on pulsatile flow.12 Absent a typical pulse oximetry wave-
form, the result is likely inaccurate. Clinicians must rely
on direct assessments of mental status, perfusion, and
general appearance to gauge the clinical condition of
LVAD recipients.
Clinical Assessment
Important elements of patient history include preced-
ing symptoms (e.g., shortness of breath, chest pain,
headache, blood in the urine or stool), the model of
their LVAD, and alarm history. Patients may be able
to identify their own equipment malfunctions or drive-
line concerns.
Assessment of airway patency, work of breathing,
and adequacy of perfusion are paramount. Clinicians
should be able to auscultate a mechanical hum and
feel vibrations generated by the LVAD. Beyond initial
assessment, clinicians should specifically look for phys-
ical signs of heart failure, decreased peripheral perfu-
sion, infection, and blood loss.
EMERGENCY MANAGEMENT SYSTEM
CHALLENGES
Field Assessment and Transport
Sending patients who are pulseless and device-depen-
dent into the community requires coordination of the
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community and prehospital providers with the
implanting center.13 As part of the certification pro-
cess, LVAD centers are required to provide first-re-
sponder education and coordination plans.11 Current
versions of the field guides for LVADs can be
accessed online at https://www.mylvad.com/medical-
professionals/resource-library/ems-field-guides.
When LVAD patients are transported to commu-
nity hospitals, the on-site team should contact the
LVAD center as soon as clinically possible. A collabo-
rative course of action can then be implemented that
best serves the patient by determining whether the
specific problem can be dealt with in a community
hospital or requires transfer.
MEDICAL EMERGENCIES IN PATIENTS
WITH LVADS
Cardiac Arrest
In patients with CF LVADs, cardiac arrest may be dif-
ficult to ascertain clinically or to differentiate from
other conditions resulting in syncope or impaired con-
sciousness. As a result, cardiac arrest resuscitation is
often delayed in patients with LVADs compared to
other medical patients.14 In the unconscious patient,
the absence of mechanical hum on precordial ausculta-
tion, inability to obtain a Doppler signal on manual
blood pressure measurement, and cardiac standstill on
echocardiography are diagnostic of cardiac arrest. In
the prehospital setting, a patient who is unresponsive
and apneic, and in whom a mechanical hum cannot
be auscultated, should be assumed to be in cardiac
arrest and receive advanced cardiac life support
(ACLS). Assessment of cardiac rhythm with a portable
monitor or electrocardiogram (ECG) is indicated in all
patients, although the LVAD may cause significant
artifact due to electrical interference.
There are varying opinions regarding both efficacy
and safety of chest compressions in patients with
LVADs, with the debate informed by case series15 and
retrospective cohort studies.14,16 Primary safety concerns
include damage to or dislodgement of the cannula or dis-
placement of the pump, resulting in catastrophic failure
and potential intrathoracic exsanguination. Neurologi-
cally intact survival without device damage is possible fol-
lowing cardiac arrest in LVAD recipients,15 and the
American Heart Association recommends bystander
CPR for LVAD recipients.17 However, based on the lack
of evidence of efficacy and equipment concerns, we do
not recommend routine use of mechanical CPR devices.
Unstable Arrhythmias
Arrhythmias, both atrial and ventricular, are common
and seldom life-threatening in patients with an LVAD.
Ventricular tachycardia (VT) is common and results
from underlying cardiomyopathy, right ventricular
(RV) failure, or mechanical decompression (e.g., suc-
tion) of the ventricle by the inflow cannula. Because
of the degree of physiologic support afforded by the
LVAD, patients may complain only of fatigue, nausea,
or light-headedness caused by arrhythmias that would
be otherwise fatal.18 Therefore, ECGs should be
obtained, even when the patient’s chief complaint is
not overtly cardiac in nature.
Clinicians treating VT or ventricular fibrillation
(VF) in the LVAD recipient are typically afforded
more time to pursue an underlying cause and consider
different treatment options. If point-of-care
Table 2











Inappropriately low speed ↑* -/↑ ↑ –/↑ Rightward Ramping speed leads to LV decompression
and AV closure
Pump thrombosis ↑ ↑ ↑ –/↑ Rightward Ramping speed does not result in expected
LV decompression or change in AV opening
Pump stoppage ↑ ↑ ↑ ↑ Rightward Reversal of flow through inflow and outflow
cannulas may be demonstrated
Aortic insufficiency ↑ — ↑ -/↑ Rightward “Moderate” AI by color flow mapping can be
hemodynamically significant
RV failure ↓ ↓ ↓ ↑ Leftward Increased RV dimensions may be associated
with moderate-severe TR
Hypovolemia ↓ ↓ ↓ ↓ Leftward
AI = aortic insufficiency; AV = aortic valve; IVC = inferior vena cava; LV = left ventricular; LVAD = left ventricular assist device; RV = right
ventricular; TR = tricuspid regurgitation.
*Increase or decrease relative to baseline study obtained when patient clinically stable.
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echocardiography is available, examination of the inflow
cannula position within the ventricle may demonstrate
the presence of an overly decompressed LV with collapse
and marked septal shift, which may trigger arrhythmias
due to myocardial irritation. This collapse may respond
to decreasing LVAD speed, allowing for increased ven-
tricular filling and migration of the septum away from the
inflow cannula. An intravenous fluid bolus can augment
preload and limit systolic ventricular collapse against the
cannula during systole as a temporizing measure in hypo-
volemic patients regardless of the degree of RV dysfunc-
tion. Table 2 summarizes abnormal echocardiographic
findings in LVAD emergencies.
Arrhythmias resulting in severe hemodynamic insta-
bility should be treated according to standard ACLS
protocols. While many patients with LVADs will have
an implantable cardioverter-defibrillator (ICD), for
those without ICDs, standard cardioversion and defib-
rillation are not contraindicated and may be per-
formed without disconnection from the device. If
possible, the pads should not be placed directly over
the device itself—anterior/posterior placement is pre-
ferred. Antiarrhythmic agents such as amiodarone
should be considered in the absence of a mechanical
cause of the arrhythmia if the patient is
hemodynamically stable. However, in refractory or
hemodynamically significant ventricular arrhythmias,
cardioversion/defibrillation will often be required.18
Myocardial Infarction
Acute myocardial infarction (MI) can occur in patients
with LVADs due to plaque rupture from underlying
coronary artery disease or coronary embolism from
ventricular or aortic root thrombus. Aortic root throm-
bus tends to occur early postimplant often in the set-
ting of a subtherapeutic INR19 and can be visualized
by transesophageal echocardiography (TEE) or com-
puted tomography (CT) angiography.20 Depending on
the cause of acute MI, management may include per-
cutaneous coronary intervention, intensification of
anticoagulation, or aortic root thrombectomy.21 Since
patients are typically fully supported by the LVAD,
chest pain may be the only presenting symptom with
heart failure being less common.
Unexplained Hypotension
Left ventricular assist systems do not have a direct way
to measure the amount of blood in the left ventricle,
making patients vulnerable to low flow complications
and hypotension (defined as a MAP or Doppler
Table 3





Low hemoglobin, hematocrit, and
platelet count  elevated INR + stool
guaiac
Low flow
Bolus IV fluids, transfusion
Hold or reverse anticoagulation





Low flow/low PI  suction
IV fluids, hold diuretics  decrease VAD speed
temporarily to avoid suction







Initiate inotropic support if RV failure
PDE-5 inhibitors may be considered if PH present
Inadequate LVAD speed High JVP
Low flow
Echo and RHC
Inadequate unloading by LVAD: high PCWP, low output
Adjust pump speed
Arrhythmia Obtain rhythm strip immediately
Sudden cardiac arrest may be difficult
to define as VAD patients can be
awake while in VF
Low Flow  suction
Use ACLS guidelines to treat arrhythmia
Mechanical obstruction/
thrombus
Elevated LDH and plasma free
hemoglobin, dark urine
Low flow  power spike
Echo
CTA to evaluate inflow and outflow cannulas
Optimize anticoagulation




High flow due to low SVR
Hold vasodilators
Add pressor support
Identify source and treat
ACLS = advanced cardiac life support; CTA = computed tomographic angiography; INR = international normalized ratio; IV = intravenous;
JVP = jugular venous pressure; LDH = lactate dehydrogenase; LVAD = left ventricular assist device; MAP = mean arterial pressure;
PCWP = pulmonary capillary wedge pressure; PE = pulmonary embolism; PH = pulmonary hypertension; RHC = right heart catheteriza-
tion; SVR = systemic vascular resistance; VF = ventricular fibrillation; WBC = white blood cell count.
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opening pressure <60 mm Hg for a CF device). Fac-
tors resulting in preload reduction (e.g., hypovolemia,
RV failure) lead to suboptimal LV filling, which in
turn can cause suboptimal flow or suction in the
inflow cannula. The pump will continue to spin with
a minimal ability to reduce speed to compensate for
decreased volume, and instability can ensue. Multiple
conditions, including sepsis, arrhythmia, pulmonary
embolism, and hypovolemia, can reduce LVAD pre-
load leading to a low-flow alarm (Table 3). In
addition, pump thrombosis or cannula obstruction
can also impair device flow.11
Low flow in the device accompanied by increasing
central venous pressure can suggest RV failure.22 In
the subacute and chronic settings, RV dysfunction can
be due to ventricular arrhythmias, volume overload,
pulmonary embolism (if INR is subtherapeutic), persis-
tent pulmonary hypertension, or tricuspid regurgita-
tion.23 Excessive pump speed and flow can also
overwhelm an already compromised right ventricle at
Figure 2. Proposed algorithm for management of trauma in a patient with an LVAD. ATLS = Advanced Trauma Life Support; BP = blood
pressure; CDC, Centers for Disease Control and Prevention; CPR = cardiopulmonary resuscitation; ECHO = echocardiogram; ECMO = extra-
corporeal membrane oxygenation; EKG = electrocardiogram; GCS = Glasgow Coma Scale; LOC = level of consciousness; LVAD = left ven-
tricular assist device; RR = respiratory rate; SPB = systolic blood pressure; VAD = ventricular assist device.
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any time following LVAD implant. In addition, use of
anesthetic agents with negative inotropic properties
(e.g., propofol) should be avoided in patients with
marginal or reduced RV function. RV failure can lead
to hemodynamic deterioration, ICD shocks, and even
cardiac arrest with VT/VF caused by impaired filling
and inadequate LVAD flow. In all low-flow cases, an
echocardiogram should be urgently obtained to assess
RV and LV dimensions and filling and rule out tam-
ponade.11 If the pump stops (see below) and the
patient is in cardiogenic shock, vasopressors along
with inotropes may be needed to support diminished
heart function.
Blunt and Penetrating Trauma
Patients with LVADs should receive the same initial
trauma evaluation as any patient24,25 in concert with
VAD system troubleshooting and cardiac surgery con-
sultation as needed. While current ATLS protocols do
not account for mechanical circulatory support, a pro-
posed accessory algorithm is presented (Figure 2).
There is ample evidence that patients who are antico-
agulated are at higher risk following trauma, but there
is no consensus regarding the management of antico-
agulation in trauma, let alone in patients with LVADs.
Invasive blood pressure monitoring should be consid-
ered early in the clinical course. If available, the
LVAD team should be consulted to ensure proper
device function. A standard chest x-ray helps to verify
pump position and basic integrity of the driveline, but
a targeted x-ray of the driveline should be performed
to ensure there has been no break in the wires. If so,
the manufacturer representative should be notified
immediately as most extracorporeal wire fractures can
be safely repaired at the bedside.26
Point of care ultrasound can evaluate for pericardial
effusion in the trauma patient, but formal echocardiog-
raphy is recommended to identify proper pump place-
ment, disturbances in the blood flow pathway, and
abnormal RV function. In addition to standard labora-
tory tests, lactate dehydrogenase (LDH) or plasma-free
hemoglobin levels should be obtained to assess for
hemolysis, which may be clues to more subtle distur-
bances in the blood flow pathway. Decisions regarding
imaging and surgical management should be based on
both hemodynamic stability and functional status of
the LVAD. If the patient is hemodynamically stable,
he or she can be closely monitored in an LVAD-ca-
pable intensive care unit or step-down unit. If the
patient is hemodynamically unstable, one should
proceed to surgery and the pump should be assessed
for salvageability.
Abdominal Pain
A patient with an LVAD presenting with abdominal
pain presents unique challenges. Patients may have ten-
derness around the driveline or the pump pocket that
may mask or mimic other intraabdominal processes.
The presentation of a driveline or pump pocket infection
(discussed below) may be mistaken for other diagnoses
and must be considered in the differential. Radiologic
examination should be guided by clinical judgment. CT
maintains its broad utility for abdominal pathology, but
artifact from the pump obscures some windows.
Bleeding Complications
Nonsurgical bleeding is a common cause of morbidity in
patients supported with LVADs. The most common
sources of bleeding include gastrointestinal (GI) and epis-
taxis, although intracranial and intrathoracic bleeding
may also occur.27-29 Platelet dysfunction, lysis of the von
Willebrand polymer, and RV dysfunction with hepatic
congestion all contribute to bleeding complications dur-
ing VAD support.30-32 The event rate of bleeding in
these patients far exceeds those observed in patients anti-
coagulated for other reasons.28
Gastrointestinal bleeding occurs in approximately
27% of patients with CF LVADs.33,34 The most com-
mon etiology in these patients is arteriovenous malfor-
mations in either the stomach or the duodenum. The
diagnostic yield of typical endoscopic procedures may
be lower since many patients have a small bowel
source of bleeding.35 If bleeding is not identified,
push enteroscopy or other methods of evaluating the
small bowel are recommended.33,35 A suggested algo-
rithm for upper/lower GI bleeding in VAD patients
has recently been published.35
Management of symptomatic GI bleeding is patients
with VADs is challenging. Withholding or reversing
anticoagulation drugs should be first discussed with
the patient’s LVAD team. Transfusion may increase
pulmonary artery pressures and worsen RV function.
In BTT patients, transfusion of leukoreduced blood is
preferable to reduce the risk of allosensitization. The
added benefit of octreotide and thalidomide in
patients with angiodysplastic lesions has not been
demonstrated, although some programs have incorpo-
rated these agents into management.36-40
Epistaxis is the second most common bleeding com-
plication in VAD patients.28 Management is the same
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as with any other anticoagulated patient, including
topical vasoconstriction, cautery, nasal packing, and
embolization as needed. Early involvement of otolaryn-
gology is advisable.
Stroke
Cerebrovascular complications remain one of the
more common adverse events experienced by patients
with LVADs.41,42 The incidence of stroke is approxi-
mately 10% per year4,43 with the risk for stroke being
highest in the early postoperative period as well as 9
to 12 months after implantation.4,44
If an acute neurologic deficit develops in a patient with
an LVAD, emergent CT of the head with angiography of
the head and neck and neurology consultation should be
obtained.11 LVAD parameters should be reviewed for
any signs of device malfunction or thrombosis. Hospitals
without VAD programs should urgently discuss the clini-
cal situation with the patient’s LVAD specialist(s) to
determine if urgent transfer is warranted, and in hemor-
rhagic strokes, to discuss discontinuation or reversal of
anticoagulation. Reversal targets an INR <1.5, and pro-
thrombin complex concentrate may be selected over
fresh-frozen plasma for more rapid effect and to avoid
excess volume.45
In patients with ischemic stroke, selective use of sys-
temic or intraarterial thrombolytic agents or an inter-
ventional neuroradiologic procedure (e.g.,
endovascular thrombectomy) may be considered, but
in the absence of prospective data, neither is routinely
recommended. Case reports of patients with throm-
boembolic stroke complicated by LVAD thrombosis
have demonstrated safe and successful use of systemic
thrombolysis.46
Infection/Sepsis
A 2011 ISHLT working group standardized the defini-
tions of LVAD infections and classified them into
LVAD-specific, LVAD-related, and non–LVAD-re-
lated.47 Non–LVAD-related infections are those not
affected by the presence of the LVAD, but happen to
occur in a patient with an LVAD such as urinary tract
infection or pneumonia. These infections are treated
in the usual fashion. LVAD-related infections refer to
infections not involving the LVAD itself, but that can
have different characteristics or implications and man-
agement when present in an LVAD patient. These
include infective endocarditis, bacteremia and medias-
tinitis.48 LVAD-specific infections involve the driveline,
pocket, pump, and/or cannula.
Approximately 14% to 35% of LVAD patients
develop percutaneous driveline infections.6,49,50 The
probability of developing an infection increases
approximately 4% for each additional month of
LVAD support.51 Infection of the percutaneous drive-
line can range from simple cellulitis to abscess forma-
tion and deep soft tissue infection. Pocket infections
refer to infection of the space housing the pump. CT
scan and/or ultrasound should be used to assess for
fluid collections around the device. Needle aspiration
can be performed, but would best be performed at the
patient’s primary LVAD center. The most common
pathogens leading to device-related infection include
Staphylococcus, Enterococcus, and Pseudomonas species.
Fungal infections are rare,52 but may be caused by
Candida species, with a few case reports of Aspergillus
and other molds.
Guidelines for the management of LVAD-associated
infections have been proposed and are based on the
type and extent of the infection.52 Patients with docu-
mented device-related infection should be treated with
targeted antibiotic therapy for 4 to 6 weeks and surgi-
cal intervention/debridement as needed. Central lines
and ICD generators and leads should be removed
according to current guidelines.53,54 LVAD removal or
exchange is associated with significant morbidity in
addition to the difficulty of removing all infected parts
and having a device-free period to allow the antibi-
otics to take effect before reimplant.
LVAD-SPECIFIC EMERGENCIES
Pump Thrombosis
Pump thrombosis can occur for a number of reasons
including inadequate anticoagulation, poorly controlled
blood pressure, and inappropriately low pump flow.55
Lasting increases in pump power by greater than 50%
from baseline may indicate thrombosis. Fibrin deposi-
tion can create drag, necessitating power increases to
maintain pump speed. Transient power spikes or sus-
tained increases in pump power accompanied by inac-
curate, elevated flow estimates may be observed.
Internal pump thrombosis may produce hemolysis
and darkened or bloody urine. Hemolysis may be
detected by elevations in serum LDH (>600 mg/dL or
2.5 times baseline), elevated free hemoglobin
(>40 mg/dL), or reduced haptoglobin levels.56 Heart
failure symptoms are often present, although nonocclu-
sive thrombi can result in significant hemolysis with-
out causing hemodynamic instability.
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Pump thrombosis is a catastrophic LVAD emer-
gency. Patients should be transported as soon as possi-
ble to the nearest LVAD center where pump exchange
or lysis can be performed. Guidelines for the detection
and management of suspected thrombosis have been
published.57 Initial management begins by providing
adequate levels of systemic anticoagulation, usually
with unfractionated heparin or a direct thrombin inhi-
bitor. Published reports of successful treatment with
heparin or bivalirudin have led some to consider these
interventions before considering surgery.58 Tissue plas-
minogen activator (TPA) use has been reported with
mixed results,59,60 and we recommend against routine
use. Pathologic studies have demonstrated that the clot
is highly organized and unlikely to respond to throm-
bin breakdown, and therefore TPA should only be
considered after contacting the implanting center.
Although medical treatment with anticoagulant agents
or fibrinolytic therapy can lead to clot resolution, the
rate of recurrence is high.61
Pump Stoppage or Failure and Driveline
Trauma
A little more than 3.5% of all deaths on LVAD sup-
port can be attributed to device malfunction.62 Fail-
ures can occur in the internal or external portion of
the driveline, patient cable, or pump controller or with
external power.
Pump stoppage occurs when there is a complete loss of
power to the pump. This can arise due to depletion of
battery power, disconnection of both power leads, or dis-
connection of the percutaneous lead from the controller.
A constant, high-pitched alarm sounds and a “red heart”
accompanies it on the pocket controller. This is an unsta-
ble situation that leads to severe regurgitation of blood
from the aorta into the LV, because the pump does not
contain valves to prevent retrograde flow. Patients will
present with symptoms of acute heart failure. The pump
will remain silent upon chest auscultation. Treatment
requires restoring power to the pump even though doing
so in patients with subtherapeutic anticoagulation risks
thromboembolism and stroke.
Driveline trauma may result in pump stoppages.
Repetitive flexing and bending of the percutaneous
lead may result in short circuits that may temporarily
or permanently stop the pump from rotating, accompa-
nied by a constant alarm.63 Temporary or more dur-
able repairs can sometimes be performed by an
industry engineer specific to each device by soldering
together disrupted wires depending on the location of
the fracture (internal vs. external).26 Complete transec-
tion of the driveline will require urgent surgical pump
replacement.
Heart Failure With an LVAD
Patients implanted with LVADs may present for emer-
gency care of acute heart failure. Typically they present
with subacute progression of symptoms or, less fre-
quently, with sudden decompensation requiring emer-
gent intervention. Several potential factors can reduce
LVAD flow leading to congestion and a low cardiac
output state.23
Inadequate LV Decompression. Inadequate
decompression of the LV can lead to heart failure in
LVAD patients. Causative factors include: 1) subopti-
mal pump speed setting, 2) increased afterload, 3)
obstruction to blood flow, 4) thrombosis of the pump
impeller, or 5) aortic insufficiency. When the LVAD
fails to adequately decrease LV volumes, imaging may
reveal LV dilation, functional mitral valve regurgita-
tion, and frequent aortic valve opening. Patients often
experience clinical symptoms of fatigue and dyspnea
and may have signs of congestion on exam. Patients
with subacute symptoms presenting to non-LVAD cen-
ters may require transfer for speed adjustments, diure-
sis, and antihypertensive therapies.
Increased afterload is most frequently caused by
poorly controlled blood pressure, which results in
reduced pump output. The monitor will display
decreased power consumption and low flow estimates.
Extreme blood pressure increases can obliterate flow
through the device, increasing the risk of cerebrovascu-
lar accidents and pump thrombosis.
Kinks or obstruction to inflow (sudden or gradual)
or outflow cannula (gradual) can lead to heart failure
with low power consumption and estimated flow dis-
played on the LVAD controller or monitor. Inflow
cannula obstruction reduces preload to the LVAD and
may occur gradually due to pannus formation or
misalignment of the cannula due to LV remodeling or
orientation of the pump pocket (i.e., changing abdomi-
nal girth). Abrupt cannula obstruction may present as
a medical emergency with sudden heart failure, syn-
cope, or shock.64,65
SUMMARY AND FUTURE DIRECTIONS
A growing number of adults with end-stage heart fail-
ure are living in the community with mechanical
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circulatory support. Like all community dwellers,
patients with left ventricular assist devices may have
urgent or emergent medical needs requiring hospital-
level care. This consensus document by the Heart Fail-
ure Society of America, Society for Academic Emer-
gency Medicine, and International Society for Heart
and Lung Transplantation aims to provide emergency
and prehospital providers with information needed to
understand the basics of continuous-flow pumps and
how to handle patients and their equipment in emer-
gency situations. More detailed information on specific
devices is available online at manufacturers’ websites
or by contacting their clinical specialists. A list of left
ventricular assist device implanting centers in the Uni-
ted States and Canada can also be found online at
www.uab.edu/medicine/intermacs/enroll/currently-en
rolled. Future studies will focus on management of
device settings, fluid resuscitation, and anticoagulation
around noncardiac surgery and trauma. The extrapola-
tion of these emergency management guidelines to a
small, but emerging population of pediatric patients
living at home with left ventricular assist devices will
also need to be explored.
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